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Transcatheter valve-in-valve replacement is an attractive
alternative to redo open-heart surgery for failing biopros-
thetic valves and is increasingly being performed in patients
with high surgical risk.1 Unlike the robust data on aortic
valve-in-valve replacement, limited experience with tricus-
pid valve-in-valve replacement has been reported.2 More-
over, the feasibility and safety of tricuspid valve-in-valve
implantation in patients with a transvenous permanent
pacemaker are largely unexplored.
Case description
A 53-year-old female patient was referred to our interdisci-
plinary transcatheter heart valve clinic for progressive
worsening of a tricuspid valve bioprosthesis (Carpentier-
Edwards, porcine, 31 mm; Edwards Lifesciences, Irvine,
CA), which was implanted 23 years before in the setting of
infective endocarditis. The degenerating tricuspid biopros-
thetic valve showed severe regurgitation and moderate
stenosis, with a mean transvalvular gradient of 8.4 mm Hg
(Figure 1). The patient’s clinical course was characterized by
right heart failure.
Her medical history was otherwise signiﬁcant for sinus
node dysfunction with atrial ﬂutter/atrial ﬁbrillation and
tachycardia–bradycardia syndrome for which a right-sided
dual-chamber pacemaker system had been implanted 2 years
previously (Medtronic Advisa DR MRI A3DR01; Med-
tronic, St Paul, MN; atrial and ventricular lead: St. Jude
Medical Tendril STS 2088TC, active ﬁxation; St Jude
Medical, St Paul, MN). Redo open heart surgery was not
considered a preferred option, because of signiﬁcant comor-
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Therefore, the patient was referred for a less-invasive trans-
catheter tricuspid valve-in-valve replacement.
Procedure
The preoperative pacemaker interrogation showed prog-
ramming to a dual-chamber non-tracking mode with rate
response (DDIR) mode (55–120 beats per minute) with
paced AV delay of 340 milliseconds and a total of 48% of
right ventricular pacing over time. There was no evidence of
prior lead or generator malfunction. Her underlying rhythm
was sinus bradycardia competing with a low atrial or
junctional rhythm and intermittent isorhythmic dissociation.
The valve-in-valve procedure was performed under gen-
eral anesthesia, and the device implantation was guided by
transesophageal echocardiography (TEE). A 20F sheath for
the delivery system was inserted in the right femoral vein.
A 29-mm Edwards SAPIEN XT (Edwards Lifesciences,
Irvine, CA) transcatheter valve was implanted with ﬂuoro-
scopic and TEE guidance inside the failed tricuspid biopros-
thesis (Figures 2A and 2B and Online Data Supplement 1A).
Valve deployment was performed under rapid right ventric-
ular pacing at a rate of 180 beats per minute by controlling
the previously implanted pacemaker (Figure 2B). Postde-
ployment ﬂuoroscopy and TEE results showed good posi-
tioning. There was an excellent hemodynamic result
(Figure 2E) with a residual transvalvular gradient of 2 mm
Hg and no evidence of any intra- or paravalvular leak
(Figure 2E). The total ﬂuoroscopy time was 34 minutes.
Results of the patient’s pacemaker interrogation before
and after the procedure are outlined in Table 1. All
parameters remained unaffected by the valve implantation.
There was a very mild, transient decrease of ventricular
sensing immediately after the valve deployment, without
safety concerns. Fluoroscopy showed a marked reduction in
the heart-synchronous swinging movements of the right
ventricular pacing lead (Figures 2C and 2D and Online Data
Supplements 1B and 1C). The clinical course post inter-
vention was favorable, and the patient was discharged 24
hours later. Results of the device interrogation at 6 weeks and
6 months post procedure are outlined in Table 1 and
Figure 3. There was a slight increase in the ventricular
pacing threshold at 6 months. Sensing and lead impedancespen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.05.004
KEY TEACHING POINTS
 Tricuspid valve-in-valve replacement is feasible in
patients with a permanent pacemaker.
 Tricuspid valve-in-valve replacement was not
associated with paravalvular leakage or
compromise of the pacemaker function during
short-term follow-up.
 The safety of tricuspid valve-in-valve procedure in
pacemaker-dependent patients is unknown.
3Steinberg et al Tricuspid Valve-in-valve Replacement and Pacemakerremained excellent. A control cineﬂuoroscopy study con-
ducted 6 weeks post implantation demonstrated a stable
valve position. After more than 6 months of follow-up, there
is still no evidence of paravalvular regurgitation.Discussion
Transcatheter valve-in-valve replacements for failing or
degenerating bioprosthetic valves are increasingly being
performed, with most procedures targeting transcatheter
aortic valve replacement.1 The feasibility for transcatheter
tricuspid valve-in-valve replacement was shown previ-
ously,3 but experience is still limited to case reports and
small series.2,4 The limitations of tricuspid valve-in-valve
procedures may include sizing problems, since many of
these devices are too large for available transcatheter
devices, and malposition. Additional concerns in patients
with pacemakers include postimplant regurgitation and lead
failure. None of the previous reports described patients with
transvenous permanent pacemakers, which is a relatively
common condition in patients with tricuspid valvular
disease.
This report demonstrates the feasibility and short-term
safety of tricuspid valve-in-valve replacement in a patient
with a permanent transvenous pacemaker. A multidiscipli-
nary approach between interventional cardiology and cardiac
electrophysiology was chosen to address procedural stepsFigure 1 Preprocedure transesophageal echocardiogram. A transesopha-
geal echocardiography long-axis view of the failing bioprosthetic tricuspid
valve with evidence of severe regurgitation.with potential for acute iatrogenic lead damage. Although the
risk is projected to be small, there is a risk of lead displace-
ment during insertion of the guide wires and the delivery
system across the tricuspid valve, despite ﬂuoroscopy
guidance. In the hands of experienced operators and in the
presence of active ﬁxation leads with remote implantation
(412 months), as was the case was the case in our patient,
the risk of having lead dislodgement during positioning of
the delivery system should probably be low. Acute failure of
the right ventricular lead is a possible complication during
valve deployment, which could crush the ventricular lead
between both valves and signiﬁcantly impair the lead
movements. The feared complications of acute mechanical
lead damage (fracture or major insulation defect) or acute
lead displacement did not occur in our patient. Nevertheless,
a transvascular temporary pacemaker system should always
be available for backup pacing, especially in pacemaker-
dependent patients. Alternatives to tricuspid valve-in-valve
procedures include redo open heart surgery or medical
treatment alone. Alternative pacemaker management could
include lead removal prior to the valve-in-valve procedure
and subsequent reimplantation, or left ventricular pacing
through a coronary sinus lead. Those two options might
be challenging in pacemaker-dependent patients, and it is
also associated with an increased risk of infection or lead
dislodgement.
Long-term concerns for the patient’s ventricular lead include
chronic insulation defects caused by ﬁne shear stress at the level
of lead ﬁxation between the 2 valve bodies as well as chronic
traction on the lead with the possibility of late-onset lead
displacement. The fact that her leads were implanted 2 years
prior to the procedure might suggest that lead displacement
should be of less concern. Tendril STS 2088TC leads have an
Optim insulation, which is composed of a copolymer of silicone
and polyurethane that has been shown to provide excellent long-
term durability and lead survival.5 Another theoretical issue
might be noise oversensing on the ventricular lead through
microfriction between the 2 valves. To date, no episode of noise
or far-ﬁeld sensing on the ventricular lead has been recorded in
our patient. Frequent device follow-up will be the key element
for early detection of lead issues that might arise from the
procedure. Late onset of paravalvular regurgitation is an addi-
tional concern and is not predictable at this stage. So far, our
patient has not developed paravalvular regurgitation. A close
follow-up with repeat imaging is recommended.
A potential advantage for patients with permanent pace-
makers might be the fact that rapid pacing for the valve
deployment can be performed through the indwelling device.
Alternatively, the tricuspid valve deployment could also be
supported by pacing through a coronary sinus catheter or a
left ventricular pacing wire, which would however require
additional hardware.2Limitations
Although our report describes the feasibility of sandwiching a
pacemaker lead during a valve-in-valve procedure, this is a
Figure 2 Valve-in-valve tricuspid valve replacement. A, B: Right anterior oblique (RAO) views during valve-in-valve implantation. A 29-mm SAPIEN XT valve
implanted inside a Carpentier-Edwards, porcine, 31-mm valve.C, D: Post–valve deployment cineﬂuoroscopy demonstrates that the RV pacing lead is now sandwiched
(white arrows) between the 2 bioprosthetic valves (black arrows: old Carpentier-Edwards valve; dashed arrows: new Edwards SAPIEN XT valve); C: Left anterior
oblique view (LAO).D: Right anterior oblique view (RAO).E: Postimplantation hemodynamic recordings show disappearance of the prominent right atrial v-wave and
only a minimal residual diastolic transvalvular gradient of 2–3 mmHg.
Heart Rhythm Case Reports, Vol 2, No 1, January 20164single case report with limited device follow-up after tricuspid
valve-in-valve implantation. Longer follow-up periods and
more patient data are warranted before general conclusions
can be drawn on the long-term safety of this procedure in
patients with pacemakers. Our approach cannot be extrapo-
lated to pacemaker-dependent patients in the absence of robust
long-term data. In addition, the ﬁndings of our case might not
apply to patients with an implantable cardioverter deﬁbrillator
or patients with multiple right ventricular leads.Transvenous lead extraction might be impossible if the
right ventricular lead is sandwiched between 2 prosthetic
valves or might carry a high risk of valve damage. However,
in a given intracardiac device–related infection, removal of
all prosthetic material is warranted, and lead extraction alone
would be unlikely to achieve infection control. Also, the
overall high procedural risk disqualiﬁes patients with such
infections for lead extraction in other situations, such as
debulking or lead failure.











Atrial 418 361 380 456 456
Ventricular 418 361 380 418 399
Sensing, mV
P waves 1.6 2.8 3.3 2.8 2.4
R waves 17.4 9.9 13.5 15.3 18.3
Pacing threshold, V/ms
Atrial 0.75/0.4 0.50/0.4 0.50/0.4 1.0/0.4 0.75/0.4
Ventricular 1.25/0.4 1.0/0.4 0.75/0.4 1.25/0.4 2.0/0.4




Figure 3 Results of pacemaker interrogation 6 months post valve-in-valve replacement.
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This case demonstrates the feasibility and short-term safety
of transcatheter tricuspid valve-in-valve implantation of an
Edwards SAPIEN XT valve in a patient with permanent right
ventricular pacemaker.Online Data Supplement 1
Valve-in-valve implantation and sandwiching of the right
ventricular pacing lead. A: Balloon inﬂation and valve
deployment. B, C: Cineﬂuoroscopy views post valve-in-
valve implantation of the Edwards SAPIEN XT valve
demonstrate a marked reduction of the RV lead swinging.
Shown are B: a right anterior oblique view (RAO) and C: a
left anterior oblique (LAO) view.Appendix
Supplementary Data
Supplementary material cited in this article is available
online at http://dx.doi.org/10.1016/j.hrcr.2015.05.004.References
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